Jisandai/Bingtonsha 2025 medical insurance price update: How patients can save treatment costs

Epclusa is a broad-spectrum antiviral drug developed by Gilead. It is mainly used to treat chronic hepatitis C (HCV) infection of all genotypes (types 1-6). Its core ingredients include Sofosbuvir 400mg and Velpatasvir 100mg. The combination of the two can effectively inhibit the replication of HCV and improve the cure rate. Epclusa is suitable for patients without cirrhosis or compensated cirrhosis, and the single-agent treatment course is usually 12 weeks; for patients with decompensated cirrhosis, it is recommended to be used in combination with ribavirin to improve the therapeutic effect.

With the official launch of Jisandai in China, it has been included in the national medical insurance directory, significantly reducing the financial burden on patients. Currently, the specifications provided by domestic hospitals and pharmacies are (400mg+100mg) × 28 tablets/box, and the price per box may be around 3,000 yuan. Patients can purchase medicines at designated hospitals with prescriptions, and the actual payment amount varies according to the reimbursement ratio of medical insurance. It is recommended that patients consult their local hospital or medical insurance bureau to learn about the latest reimbursement policies.

For patients who want to further save on treatment costs, the third-generation generic drugs produced in India and Bangladesh provide a more affordable option. The ingredients, dosage and efficacy of these generic drugs are basically the same as those of the original drugs. International clinical data also supports their efficacy. The price is about 800 yuan per box (28 tablets), which is suitable for a 12-week treatment course. When purchasing, make sure to purchase through formal channels, such as overseas medical institutions or compliant pharmacies, to avoid the risk of counterfeit drugs.

In general, Jisandai’s medical insurance coverage has greatly benefited domestic patients, and the existence of overseas generic drugs also provides a viable alternative for patients with limited financial conditions. When choosing a drug purchase channel, patients should make the optimal decision based on their personal condition, financial situation, medication safety, and doctor's advice.

Reference: https://www.epclusa.com/